Fujifilm has bought Biogen ApS’ Copenhagen facility for US$890 million.
Fujifilm Diosynth Biotechnologies has acquired Biogen Manufacturing ApS near Copenhagen, Denmark for US$890 million in cash, according to a company press release that was issued on Aug. 1, 2019. This is the fourth facility that the contract development and manufacturing organization (CDMO) has acquired since it was established in 2011.
The new site has nearly 800 employees and includes a large-scale production facility with six 15,000-L bioreactors; an assembly, labeling and packaging facility; and quality control laboratories and warehouses.
“We will seek to continue the further advancement of the pharmaceutical industry by serving our range of diverse customers’ needs through combining resources of the Biogen (Denmark) Manufacturing ApS and Fujifilm,” said Takatoshi Ishikawa, executive vice president and general manager of Fujifilm Corporation’s Bio CDMO division, in the press release.
Source: Fujifilm
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.